March is National Kidney Month – a time to raise awareness and learn more about kidney health and kidney disease. Earlier in ...

Novo Nordisk already has broad FDA approvals in hand for its injected semaglutide products Ozempic and Wegovy to reduce the ...

In brief ... 💊 A new international clinical trial found that oral semaglutide reduces the risk of major cardiovascular ...

Novo Nordisk's Ozempic has been shown to improve waking distance and quality of life in people with type 2 diabetes (T2D) and ...

But keep in mind that if you have type 2 diabetes and heart disease, using Ozempic also reduces your risk of heart attack and stroke. And if you have chronic kidney disease, Ozempic can reduce ...

Stopping Ozempic injections for weight loss can cause weight gain and a possible increase in blood sugar and blood pressure. To restart Ozempic treatment, a doctor will slowly increase your dose ...

Too often, patients with chronic kidney disease get diagnosed too late – if at all. Addressing risk factors early can stave ...

Novo Nordisk has submitted a supplemental application to the FDA for Rybelsus 14 mg to lower cardiovascular risk in adults ...

Treatment with semaglutide improved maximum walking distance in patients with type 2 diabetes (T2D) and symptomatic peripheral artery disease (PAD), according to results from the STRIDE trial ...

Novo Nordisk's Phase 3b STRIDE trial shows Ozempic improves walking distance in peripheral artery disease, while the SOUL ...

Results from the SUMMIT trial suggest that tirzepatide is as effective in preventing heart failure events in those with ...

For a disease afflicting 35.5 million people in the U.S., chronic kidney disease flies under the radar. Only half the people who have it are formally diagnosed. The consequences of advanced ...